• Profile
Close

Efficacy and safety of tribendimidine vs praziquantel against Opisthorchis viverrini in Laos: An open-label, randomised, non-inferiority, phase 2 trial

The Lancet Infectious Diseases Feb 01, 2018

Sayasone S, et al. - In participants with O viverrini infection, the efficacy and safety of a single, oral dose of tribendimidine were compared with praziquantel administered in two doses. Observations revealed that compared to praziquantel, tribendimidine had a slightly lower cure rate and was not non-inferior. However, tribendimidine showed a similar egg reduction rate to praziquantel and resulted in fewer adverse events. Thereby suggesting that it might complement praziquantel in O viverrini control programmes, particularly in settings co-endemic for hookworm.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay